<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Liminatus Pharma, Inc. Class A Common Stock — News on 6ix</title>
<link>https://6ix.com/company/liminatus-pharma-inc-class-a-common-stock</link>
<description>Latest news and press releases for Liminatus Pharma, Inc. Class A Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 17 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/liminatus-pharma-inc-class-a-common-stock" rel="self" type="application/rss+xml" />
<item>
<title>Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody</title>
<link>https://6ix.com/company/liminatus-pharma-inc-class-a-common-stock/news/liminatus-pharma-announces-planned-phase-1-clinical-trial-of-iba101-a-next-generation-cd47-blocking-antibody</link>
<guid isPermaLink="true">https://6ix.com/company/liminatus-pharma-inc-class-a-common-stock/news/liminatus-pharma-announces-planned-phase-1-clinical-trial-of-iba101-a-next-generation-cd47-blocking-antibody</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>CERRITOS, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Liminatus today announced plans to initiate a Phase 1 clinical trial evaluating IBA101, a next-generation</description>
</item>
<item>
<title>Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering</title>
<link>https://6ix.com/company/liminatus-pharma-inc-class-a-common-stock/news/liminatus-pharma-inc-announces-pricing-of-dollar40-million-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/liminatus-pharma-inc-class-a-common-stock/news/liminatus-pharma-inc-announces-pricing-of-dollar40-million-public-offering</guid>
<pubDate>Tue, 17 Feb 2026 13:44:00 GMT</pubDate>
<description>CERRITOS, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN) (“Liminatus” or the “Company”), a pre-clinical stage immuno-oncology company developing next-generation CD47-blockade therapies, today announced the pricing of its best-efforts public offering of 13,813,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 20,719,500 shares of common stock, at a combined public offering price of $0.29 per share (or $0.2899 pe</description>
</item>
<item>
<title>Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation</title>
<link>https://6ix.com/company/liminatus-pharma-inc-class-a-common-stock/news/liminatus-pharma-inc-nasdaq-limn-140400782</link>
<guid isPermaLink="true">https://6ix.com/company/liminatus-pharma-inc-class-a-common-stock/news/liminatus-pharma-inc-nasdaq-limn-140400782</guid>
<pubDate>Thu, 30 Oct 2025 14:04:00 GMT</pubDate>
<description>LA PALMA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today that it has entered into a Memorandum of Understanding (MOU) with Capital Trust Group Limited (CTG), a New Zealand-based investment management firm, for a USD 30,000,000 equity financing via an earn-out mechanism to support Liminatus’s research and development of advanced immunotherapy assets. Subje</description>
</item>
<item>
<title>Liminatus Pharma Inc. to Launch “American BNB Strategy” Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative</title>
<link>https://6ix.com/company/liminatus-pharma-inc-class-a-common-stock/news/liminatus-pharma-inc-to-launch-american-bnb-strategy-subsidiary-and-target-up-to-dollar500-million-fund-for-bnb-investment-as-part-of-crypto-market-initiative</link>
<guid isPermaLink="true">https://6ix.com/company/liminatus-pharma-inc-class-a-common-stock/news/liminatus-pharma-inc-to-launch-american-bnb-strategy-subsidiary-and-target-up-to-dollar500-million-fund-for-bnb-investment-as-part-of-crypto-market-initiative</guid>
<pubDate>Mon, 28 Jul 2025 04:00:00 GMT</pubDate>
<description>Liminatus Identifies BNB Coin as Its Primary Strategic Target for Digital Asset Allocation, with Plans to Aggressively Accumulate and Hold Up to $500 Million</description>
</item>
<item>
<title>Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies</title>
<link>https://6ix.com/company/liminatus-pharma-inc-class-a-common-stock/news/liminatus-pharma-inc-evaluates-formation-123100239</link>
<guid isPermaLink="true">https://6ix.com/company/liminatus-pharma-inc-class-a-common-stock/news/liminatus-pharma-inc-evaluates-formation-123100239</guid>
<pubDate>Fri, 25 Jul 2025 12:31:00 GMT</pubDate>
<description>Strategic Internal Review initiated for treasury diversification through a prospective digital asset subsidiary — no entity formed, no capital committedLA PALMA, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced that its Board of Directors and executive team have formally initiated a strategic review to explore the potential formation of a</description>
</item>
<item>
<title>Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy</title>
<link>https://6ix.com/company/liminatus-pharma-inc-class-a-common-stock/news/liminatus-pharma-inc-takes-next-123100805</link>
<guid isPermaLink="true">https://6ix.com/company/liminatus-pharma-inc-class-a-common-stock/news/liminatus-pharma-inc-takes-next-123100805</guid>
<pubDate>Thu, 24 Jul 2025 12:31:00 GMT</pubDate>
<description>Agreement with Digital Offering Advances Company's plan to assess innovative treasury-backed financing pathsLA PALMA, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced it has entered into an engagement agreement with Digital Offering LLC, a FINRA- and SEC-registered broker-dealer, to serve as its exclusive placement agent in connection with</description>
</item>
<item>
<title>Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy</title>
<link>https://6ix.com/company/liminatus-pharma-inc-class-a-common-stock/news/liminatus-pharma-inc-initiates-strategic-173000988</link>
<guid isPermaLink="true">https://6ix.com/company/liminatus-pharma-inc-class-a-common-stock/news/liminatus-pharma-inc-initiates-strategic-173000988</guid>
<pubDate>Tue, 22 Jul 2025 17:30:00 GMT</pubDate>
<description>Preclinical-stage biotech company explores digital asset treasury opportunities to enhance capital efficiency while maintaining core focus on immunotherapy innovationLA PALMA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced that it has initiated a strategic review to evaluate the potential inclusion of regulated digital asset strategies a</description>
</item>
</channel>
</rss>